The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Avidity Biosciences Inc shares valued at $5,004,676 were purchased by ERIC MOSBROOKER on Aug 06 ’25. At $38.26 per share, ERIC MOSBROOKER acquired 130,807 shares.
Also, STEVEN GEORGE HUGHES purchased 81,434 shares, netting a total of over 3,115,665 in proceeds.
Before that, ARTHUR LEVIN had added 107,500 shares to its account. In a trade valued at $4,112,950, the Director bought Avidity Biosciences Inc shares for $38.26 each.
Analysts at Bernstein started covering the stock with ‘”an Outperform”‘ outlook in a report released in late June. As of June 17, 2025, Wolfe Research has initiated its “an Outperform” rating for RNA. Earlier on June 11, 2025, Raymond James initiated its rating. Their recommendation was “a Strong buy” for RNA stock.
Analyzing RNA Stock Performance
On last trading session, Avidity Biosciences Inc [NASDAQ: RNA] plunged -1.53% to $47.52. The stock’s lowest price that day was $46.0498, but it reached a high of $48.1 in the same session. During the last five days, there has been a surge of approximately 29.45%. Over the course of the year, Avidity Biosciences Inc shares have jumped approximately 12.61%.
Is Avidity Biosciences Inc subject to short interest?
Stocks of Avidity Biosciences Inc saw a sharp steep in short interest on 2025-07-15 dropping by 84374.0 shares to 16.26 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 16.34 million shares. A decline of -0.52% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.18 of the overall float, the days-to-cover ratio (short ratio) decline to 9.18.
Which companies own the most shares of Avidity Biosciences Inc (RNA)?
In terms of Avidity Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 70 in the next 12 months, up nearly 45.05% from the previous closing price of $48.26. Analysts anticipate Avidity Biosciences Inc stock to reach 70 by 2025, with the lowest price target being 70. In spite of this, 6 analysts ranked Avidity Biosciences Inc stock as Buy at the end of 2025. On March 13, 2025, Citigroup assigned a price target of “a Buy” to the stock and initiated coverage with a $70.
